On the acceptability of biopharmaceuticals

Science and Engineering Ethics

Volumn 2, Issue 3, 1996, Pages 291-306

  Spier, Raymond ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Acceptability; Biopharmaceuticals; Ethics; Psychology; Regulators

Indexed keywords

BIOLOGICAL PRODUCT; DRUG;

ARTICLE; ATTITUDE; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG INDUSTRY; DRUG TOXICITY; GENETIC ENGINEERING; GENETICS AND REPRODUCTION; GOVERNMENT REGULATION; HEALTH CARE AND PUBLIC HEALTH; HUMAN; HUMAN EXPERIMENT; INSTITUTIONAL ETHICS; LEGAL APPROACH; MICROBIOLOGY; PSYCHOLOGY; RISK; RISK ASSESSMENT; SOCIAL CONTROL; STANDARD; TRANSGENIC ORGANISM;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH; LEGAL APPROACH;

ATTITUDE; BIOLOGICAL PRODUCTS; DRUG INDUSTRY; DRUG TOXICITY; ETHICS, INSTITUTIONAL; GENETIC ENGINEERING; GOVERNMENT REGULATION; HUMAN EXPERIMENTATION; HUMANS; MICROBIOLOGY; ORGANISMS, GENETICALLY MODIFIED; PHARMACEUTICAL PREPARATIONS; PSYCHOLOGY; REFERENCE STANDARDS; RISK; RISK ASSESSMENT; SOCIAL CONTROL, FORMAL;

EID: 0030176992     PISSN: 13533452     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02583915     Document Type: Article

References (22)

1. Vagelos, P.R. (1991) Are prescription drug prices too high. Science 252: 1080-1084.
2. de Maris (1993) Review of the Pharmaceutical Industry: Costs. Document No. OTA-H-523 (February 1993), U.S. Government Publication.
3. Lee, K.B. and Bunill, G.S. (1994) Biotech 95: Reform, Restructure, Renewal, The Ernst and Young Ninth Annual Report on the Biotechnology Industry, p14.
4. Joint ESACT-IABS meeting on the use of heteroploid and other cell substrates for the production of biologicals. (1982) Developments in Biological Standardization vol 50, Karger, Basel, Switzerland.
5. Continuous cell lines as substrates for biologicals. (1989) Developments in Biological standardization vol 70, Karger, Basel, Switzerland.
6. Virological aspects of the safety of biological products (1991) Developments in Biological Standardization, vol 75 Karger, Basel, Switzerland.
7. Dunlop, D. (1973) Medicines in our time, The Nuffield Provincial Hospital's Trust, pp 67-89.
8. Goldenthal, K. (1995) FDA perspective on evaluation of new vaccine technology, In: Vaccines: New Technologies and Applications (Proceedings of a Meeting held in Alexandria, VA, 20-22 March 1995), published by Cambridge Health Institute, Waltham, MA.
9. Lowrance, W.W. (1976) Of Acceptable Risk, William Kaufmann, Inc., Los Altos CA, pp 75-86.
10. Kletz, T.A. (1981) Benefits and risks, their assessment in relation to human needs, In: Griffiths, R.F., ed., Dealing with risk, The planning, management and acceptability of technological risk, Manchester University Press, UK, pp36-53.
11. Report of a Royal Society Study Group (1983) Risk assessment. The Royal Society, London, pp 94-148.
12. Singer, P., ed. (1993) A Companion to Ethics, Blackwell, Oxford.
13. Genesis. 1:22.
14. Evangelicum Vitae (1995) Catholic Truth Society, London.
15. McNeill, W.H. (1977) Plagues and Peoples, Blackwell, Oxford,UK.
16. Gorman, C. (1995) Has gene therapy stalled, Time (9 October): pp50-51.
17. Fenner, F. (1982) A successful eradication campaign. Global eradication of smallpox. Reviews of Infectious Diseases 4:916-930.
18. de Quadros, C.A. (1994) Strategies for disease control/eradication in the Americas. In: Cutts, F.T. and Smith, P.G. eds., Vaccination and World Health, John Wiley & Sons Ltd, New York, pp 17-36.
19. The State of the World's Children 1996, UNICEF, Oxford University Press, UK, pp 98-99.
20. Swartz, R.W. (1985) Penicillins. In: Moo-Young, M. ed., Comprehensive Biotechnology, vol 3. Pergamon Press, Oxford, UK, pp 8-47.
21. Kelves, D.J. (1985) In the Name of Eugenics, University of California Press, Berkeley,CA, pp 426.
22. Rolin, B.E. (1995) The Frankenstein Syndrome, Cambridge University Press, UK, pp 61-2.